EYLEA Sales Forecast And Market Size Analysis 2020-2034: Highlights Growth Opportunities Across Major Ophthalmology Markets
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "EYLEA Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of EYLEA (aflibercept) and EYLEA HD across the seven major pharmaceutical markets. Coverage includes the United States, Germany, France, Italy, Spain, the United Kingdom and Japan, with historical market analysis from 2020 and sales forecasts through 2034.
The report examines EYLEA's commercial performance, clinical profile, regulatory milestones, pricing, reimbursement environment and competitive positioning across major retinal diseases. It also evaluates future market opportunities associated with label expansion, extended dosing regimens and potential indications, including polypoidal choroidal vasculopathy.
Key Factors Supporting EYLEA Market Growth
EYLEA maintains an established position in the global ophthalmology market, supported by a substantial patient population requiring ongoing treatment for serious retinal diseases. Core indications include neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and macular edema following retinal vein occlusion.
- Standard-dose EYLEA generated approximately $4.77 billion in U.S. sales during 2024. The combined U.S. EYLEA and EYLEA HD franchise generated approximately $5.97 billion in 2024. EYLEA HD contributed approximately $1.2 billion in U.S. sales during 2024. Reported EYLEA HD growth included a 29% year-over-year increase in the second quarter of 2025, with stronger growth recorded during earlier 2025 reporting periods.
EYLEA HD, the 8 mg formulation approved in 2023, is expected to remain a primary growth driver for the franchise. Its clinical profile supports longer treatment intervals for eligible patients, potentially improving treatment persistence and reducing the frequency of intravitreal injections compared with more frequent anti-VEGF dosing schedules.
Clinical Profile and Lifecycle Management
EYLEA is a recombinant fusion protein developed by Regeneron Pharmaceuticals and Bayer. It binds vascular endothelial growth factor A and placental growth factor, inhibiting angiogenesis and vascular permeability. Standard EYLEA is administered by intravitreal injection, with dosing determined by indication, treatment phase and patient response.
Pivotal clinical programs, including VIEW and VIVID/VISTA, established EYLEA's efficacy and safety across key retinal indications. Its long-term clinical use and extensive real-world evidence have supported strong physician confidence and continued adoption. Reported adverse reactions include conjunctival hemorrhage, eye pain and increased intraocular pressure, while serious risks associated with intravitreal administration require appropriate monitoring.
Ongoing lifecycle management strategies include expanded retinal vein occlusion use, greater dosing flexibility and broader adoption of EYLEA HD. In February 2026, Regeneron Pharmaceuticals announced presentations from its ophthalmology portfolio and pipeline for the virtual Angiogenesis, Exudation, and Degeneration annual meeting, including clinical data evaluating EYLEA HD 8 mg in serious retinal diseases.
Global EYLEA Market Outlook
Regeneron commercializes EYLEA in the United States, while Bayer supports commercialization outside the United States. International expansion opportunities are being supported by aging populations, improving diagnosis, broader access to retinal care and the increasing prevalence of diabetes-related eye disease.
Demographic and epidemiological trends are expected to expand the addressable patient population through 2034. However, the EYLEA market will continue to face pressure from biosimilars, competing anti-VEGF products, emerging long-acting therapies, pricing constraints and evolving reimbursement policies.
Scope of the EYLEA Market Report
- Historical and forecast EYLEA sales analysis from 2020 through 2034. Market size forecasts across the United States, EU4, the United Kingdom and Japan. Product profiles covering mechanism of action, dosage, administration and clinical development. Analysis of EYLEA and EYLEA HD regulatory milestones and development activities. Clinical trial assessment by intervention, condition, status and anticipated completion date. Regional pricing, reimbursement and cost-per-patient analysis. Patent coverage, anticipated biosimilar or generic entry and potential pricing impact. Competitive intelligence covering marketed products and late-stage emerging therapies. SWOT analysis, analyst perspectives and strategic market positioning. Assessment of partnerships, licensing agreements and other commercial developments.
EYLEA Competitive and Commercial Assessment
The report evaluates EYLEA's differentiation based on efficacy, safety, dosing flexibility, physician familiarity and extensive clinical evidence. It also assesses the number of competing therapies in development, expected launch timelines and the potential impact of new products on EYLEA sales and market share.
Forecast scenarios consider the transition from standard-dose EYLEA to EYLEA HD, adoption of extended treatment intervals, regional prescribing trends, competitive pricing and reimbursement policies. The analysis also reviews potential peak sales, market penetration and the commercial implications of future regulatory decisions.
Research Methodology
The EYLEA market forecast is based on primary and secondary research, internal databases and analysis conducted by industry specialists. Sources include global regulatory authorities, clinical trial registries, company disclosures, peer-reviewed publications, trade journals, industry associations, market databases and other publicly available materials. Findings are validated through cross-source analysis to support market estimates and forecast assumptions.
Strategic Value of the Report
The report is designed to support pharmaceutical companies, investors, healthcare organizations and other stakeholders evaluating the EYLEA market through 2034. It provides actionable insight into sales potential, regional opportunities, competitive threats, clinical differentiation, pricing trends and the factors likely to influence the future performance of the EYLEA franchise.
By combining clinical, regulatory and commercial analysis, the report offers a detailed view of EYLEA's current market position and its long-term prospects within the global retinal disease treatment landscape.
Key Topics Covered
1. Report Introduction
2. EYLEA Overview in approved indications like Branch retinal vein occlusion, Central retinal vein occlusion, Choroidal neovascularisation, Colorectal cancer, Diabetic macular oedema, Diabetic retinopathy, and Glaucoma; as well as potential indication like Polypoidal choroidal vasculopathy
2.1. Product Detail
2.2. EYLEA Clinical Development
2.2.1. EYLEA Clinical studies
2.2.2. EYLEA Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. EYLEA Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging EYLEA Therapies)
5. EYLEA Market Assessment
5.1. EYLEA Market Outlook in approved and potential indications
5.2. 7MM Analysis
5.2.1. EYLEA Market Size in the 7MM for approved and potential indications
5.3. Country-wise Market Analysis
5.3.1. EYLEA Market Size in the United States for approved and potential indications
5.3.2. EYLEA Market Size in Germany for approved and potential indications
5.3.3. EYLEA Market Size in France for approved and potential indications
5.3.4. EYLEA Market Size in Italy for approved and potential indications
5.3.5. EYLEA Market Size in Spain for approved and potential indications
5.3.6. EYLEA Market Size in the United Kingdom for approved and potential indications
5.3.7. EYLEA Market Size in Japan for approved and potential indications
6. EYLEA SWOT Analysis
7. Analysts' Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: EYLEA, Clinical Trial Description, 2023
Table 2: EYLEA, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: EYLEA's pricing and cost Assumptions
Table 6: EYLEA's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: EYLEA Market Size in the US, in USD million (2020-2034)
Table 8: EYLEA Market Size in Germany, in USD million (2020-2034)
Table 9: EYLEA Market Size in France, in USD million (2020-2034)
Table 10: EYLEA Market Size in Italy, in USD million (2020-2034)
Table 11: EYLEA Market Size in Spain, in USD million (2020-2034)
Table 12: EYLEA Market Size in the UK, in USD million (2020-2034)
Table 13: EYLEA Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: EYLEA's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: EYLEA Market Size in the United States, USD million (2020-2034)
Figure 3: EYLEA Market Size in Germany, USD million (2020-2034)
Figure 4: EYLEA Market Size in France, USD million (2020-2034)
Figure 5: EYLEA Market Size in Italy, USD million (2020-2034)
Figure 6: EYLEA Market Size in Spain, USD million (2020-2034)
Figure 7: EYLEA Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: EYLEA Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment